Industry news that matters to you.  Learn more

The CFIDS Association of America Breaks Ground on Its ‘Institute Without Walls’ to Transform Chronic Fatigue Syndrome Research

The CFIDS Association of America recently announced new additions to its comprehensive research initiative to advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS): five new grant awards, two new projects using resources from a central biobank and curation of a biomarker “hit list” to guide future research. The new investments total $2 million.

Lundbeck Canada Donates $2.7 Million to Fund Ground-breaking Depression Research

Lundbeck Canada has made a landmark donation of $2.7 million to support ground-breaking research at the University Health Network to identify biomarkers (biological markers) that will enhance the diagnosis and treatment of patients suffering from major depression and bipolar disorder.

National Parkinson Foundation Awards More Than $1 Million for Research

The National Parkinson Foundation (NPF) has awarded more than $1 million dollars in clinical research projects in 2011. Through NPF’s individual investigators awards program, NPF is supporting work to advance three key areas of Parkinson’s disease (PD): 1) an advanced biomarker study, 2) a clinical trial to treat memory impairment, and 3) a study of the effectiveness of a treatment for sleep apnea in PD.

Takeda Pharmaceutical Licenses Predictive Alzheimer’s Biomarker from Zinfandel

Takeda Pharmaceutical Company recently announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel Pharmaceutical’s TOMM40 assay as a biomarker for the risk of Alzheimer’s disease.

Mayo Clinic Finds Seizure Generation in Brain is Isolated from Surrounding Brain Regions

Mayo Clinic researchers found that the part of the brain generating seizures in individuals with epilepsy is functionally isolated from surrounding brain regions. The researchers hope this finding could be a clinical biomarker to help identify individuals with abnormal brain function. This study was presented at the American Epilepsy Society’s annual meeting in San Antonio on Dec. 4.